What is a stock summary page? Click here for an overview.
Business Description

Galapagos NV
NAICS : 541714
SIC : 2834
ISIN : BRG1LPBDR002
Share Class Description:
BSP:G1LP34: BRDRCompare
Compare
Traded in other countries / regions
GLPG.NetherlandsGLPG.USA0JXZ.UKGXE.GermanyGLPG.AustriaG1LP34.BrazilGLPG.BelgiumGLPG.Mexico IPO Date
2020-10-19Description
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 265.96 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-EBITDA | -5.39 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.6 | |||||
Beneish M-Score | -1.33 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | 10.7 | |||||
3-Year Book Growth Rate | 2.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | -48.43 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -3.67 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.13 | |||||
9-Day RSI | 50.45 | |||||
14-Day RSI | 47.97 | |||||
3-1 Month Momentum % | -5.49 | |||||
6-1 Month Momentum % | -10.19 | |||||
12-1 Month Momentum % | -5.85 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.97 | |||||
Quick Ratio | 9.81 | |||||
Cash Ratio | 9.3 | |||||
Days Inventory | 700.74 | |||||
Days Sales Outstanding | 55.62 | |||||
Days Payable | 1302.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 0.23 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.35 | |||||
Operating Margin % | -68.33 | |||||
Net Margin % | 26.88 | |||||
FCF Margin % | -143.14 | |||||
ROE % | 2.58 | |||||
ROA % | 1.74 | |||||
ROIC % | -9.01 | |||||
3-Year ROIIC % | 34.82 | |||||
ROC (Joel Greenblatt) % | -1.71 | |||||
ROCE % | -0.06 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 19.75 | |||||
Forward PE Ratio | 156.25 | |||||
PS Ratio | 5.29 | |||||
PB Ratio | 0.5 | |||||
Price-to-Tangible-Book | 0.55 | |||||
EV-to-EBIT | 811.31 | |||||
EV-to-EBITDA | 811.31 | |||||
EV-to-Revenue | -6.4 | |||||
EV-to-FCF | 4.1 | |||||
Price-to-GF-Value | 0.53 | |||||
Price-to-Projected-FCF | 0.44 | |||||
Price-to-Median-PS-Value | 0.3 | |||||
Price-to-Net-Current-Asset-Value | 0.69 | |||||
Price-to-Net-Cash | 0.78 | |||||
Earnings Yield (Greenblatt) % | 0.12 | |||||
FCF Yield % | -27.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galapagos NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 1,639.568 | ||
EPS (TTM) (R$) | 0.296 | ||
Beta | 0.12 | ||
3-Year Sharpe Ratio | -0.88 | ||
3-Year Sortino Ratio | -1.04 | ||
Volatility % | 31.1 | ||
14-Day RSI | 47.97 | ||
14-Day ATR (R$) | 0.121188 | ||
20-Day SMA (R$) | 7.2355 | ||
12-1 Month Momentum % | -5.85 | ||
52-Week Range (R$) | 6.46 - 9.06 | ||
Shares Outstanding (Mil) | 1,317.94 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Galapagos NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Galapagos NV Stock Events
Event | Date | Price (R$) | ||
---|---|---|---|---|
No Event Data |
Galapagos NV Frequently Asked Questions
What is Galapagos NV(BSP:G1LP34)'s stock price today?
The current price of BSP:G1LP34 is R$7.18. The 52 week high of BSP:G1LP34 is R$9.06 and 52 week low is R$6.46.
When is next earnings date of Galapagos NV(BSP:G1LP34)?
The next earnings date of Galapagos NV(BSP:G1LP34) is 2025-04-23.
Does Galapagos NV(BSP:G1LP34) pay dividends? If so, how much?
Galapagos NV(BSP:G1LP34) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |